Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avugane valproic acid: Phase II data

A 12-week, double-blind, European Phase II trial in 70 patients showed that 0.5%, 3% and

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE